No connection

Search Results

NMTC vs RADX

NMTC
NeuroOne Medical Technologies Corporation
BEARISH
Price
$0.73
Market Cap
$37.0M
Sector
Healthcare
AI Confidence
80%
RADX
Radiopharm Theranostics Limited
BEARISH
Price
$4.58
Market Cap
$36.1M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
NMTC
--
RADX
--
Forward P/E
NMTC
-2.61
RADX
-1.75
P/B Ratio
NMTC
5.75
RADX
1.43
P/S Ratio
NMTC
3.16
RADX
2.22
EV/EBITDA
NMTC
-4.55
RADX
-413.38

Profitability

Gross Margin
NMTC
22.03%
RADX
-136.51%
Operating Margin
NMTC
-59.02%
RADX
-423.75%
Profit Margin
NMTC
-58.28%
RADX
-286.16%
ROE
NMTC
-146.27%
RADX
-92.1%
ROA
NMTC
-63.4%
RADX
-28.33%

Growth

Revenue Growth
NMTC
-11.7%
RADX
154.5%
Earnings Growth
NMTC
--
RADX
--

Financial Health

Debt/Equity
NMTC
0.04
RADX
--
Current Ratio
NMTC
6.41
RADX
3.01
Quick Ratio
NMTC
4.95
RADX
3.0

Dividends

Dividend Yield
NMTC
--
RADX
--
Payout Ratio
NMTC
0.0%
RADX
0.0%

AI Verdict

NMTC BEARISH

NMTC presents a contradictory profile with a stable Piotroski F-Score of 6/9 and a very strong liquidity position (Current Ratio 6.41), yet it suffers from severe operational decay. The company is experiencing negative revenue growth (-11.70% YoY) and deep losses, evidenced by an ROE of -146.27%. While the balance sheet is clean with minimal debt (D/E 0.04), the bearish technical trend and consistent lack of profitability make it a high-risk speculative play.

Strengths
Very low Debt/Equity ratio (0.04)
Strong short-term liquidity (Current Ratio 6.41)
Stable Piotroski F-Score (6/9) indicating some internal financial improvements
Risks
Negative revenue growth (-11.70% YoY and -11.65% Q/Q)
Severe negative profit margins (-58.28%)
High Price-to-Book ratio (5.75) relative to lack of earnings
RADX BEARISH

RADX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation benchmarks like the Graham Number due to negative earnings. While the company shows impressive YoY revenue growth of 154.50% and maintains strong short-term liquidity (Current Ratio 3.01), these are overshadowed by a catastrophic negative gross margin of -136.51%. The stock is in a severe technical downtrend, having collapsed from a 52-week high of $16.25 to $4.58, suggesting a significant loss of investor confidence despite optimistic analyst price targets.

Strengths
Exceptional YoY revenue growth of 154.50%
Strong liquidity position with a Current Ratio of 3.01
Low Price-to-Sales ratio (2.22) relative to biotech peers
Risks
Negative gross margins indicate the cost of producing goods exceeds revenue
Severe operating losses with an operating margin of -423.75%
Extreme technical weakness (Technical Trend score 0/100)

Compare Another Pair

NMTC vs RADX: Head-to-Head Comparison

This page compares NeuroOne Medical Technologies Corporation (NMTC) and Radiopharm Theranostics Limited (RADX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile